Last reviewed · How we verify
KRYSTEXXA®
Krystexxa works by targeting a specific biological pathway to treat a particular condition.
Krystexxa is a small molecule drug developed by Selecta Biosciences, Inc. However, due to the lack of available information, its target, drug class, and approved indications are unknown. The commercial status of Krystexxa is also unclear, as it is not stated whether it is patented or has generic manufacturers. As a result, key safety considerations and its half-life, bioavailability, and off-patent status cannot be determined. Further research is necessary to provide a comprehensive summary of Krystexxa.
At a glance
| Generic name | KRYSTEXXA® |
|---|---|
| Also known as | Pegloticase |
| Sponsor | Selecta Biosciences, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| Annual revenue | 900 |
Mechanism of action
Unfortunately, without more information, it's difficult to explain how Krystexxa works in plain English. However, in general, small molecule drugs like Krystexxa are designed to interact with specific proteins or enzymes in the body to produce a therapeutic effect. This can help to either block or enhance the activity of these proteins to treat a range of conditions.
Approved indications
- Gout
Common side effects
- Gout flare
- Asthenia
- Malaise
- Peripheral swelling
Serious adverse events
- Anaphylaxis
- Infusion Reactions
Key clinical trials
- A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout (PHASE4)
- A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL) (PHASE4)
- Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout (PHASE4)
- Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout (PHASE4)
- A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy (PHASE2)
- Observational Study of the Use of Pegloticase (KRYSTEXXA®) in Refractory Chronic Gout
- Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KRYSTEXXA® CI brief — competitive landscape report
- KRYSTEXXA® updates RSS · CI watch RSS
- Selecta Biosciences, Inc. portfolio CI